Myomo Inc. (MYO)
| Market Cap | 15.76M |
| Revenue (ttm) | 15.39M |
| Net Income (ttm) | -10.87M |
| Shares Out | 6.88M |
| EPS (ttm) | -1.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,691 |
| Open | 2.40 |
| Previous Close | 2.41 |
| Day's Range | 2.26 - 2.49 |
| 52-Week Range | 2.26 - 14.35 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 18.36 (+701.7%) |
| Earnings Date | May 11, 2022 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cor...
Financial Performance
In 2021, Myomo's revenue was $13.86 million, an increase of 82.72% compared to the previous year's $7.58 million. Losses were -$10.37 million, -10.30% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for MYO stock is "Buy." The 12-month stock price forecast is 18.36, which is an increase of 701.75% from the latest price.
News
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Myomo Reports First Quarter 2022 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo to Report First Quarter Financial Results on May 11, 2022
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo To Participate in Two March Investor Conferences
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Independent Research with Myomo's MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Ch...
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo to Present at the Sidoti Winter Small Cap Conference
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Provides Update on MyoPro® Insurance Reimbursement
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Announces MyoPro® 2+
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. (MYO) Reports Q3 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo Third Quarter 2021 Financial Results Feature Record Revenue
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo to Report Third Quarter 2021 Financial Results on November 10, 2021
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Will Myomo, Inc. (MYO) Report Negative Q3 Earnings? What You Should Know
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5th
BOSTON, MA / ACCESSWIRE / September 28, 2021 / Myomo, Inc. (NYSE American:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering fro...
Myomo, Inc. Announces Granting of Patents in China and Hong Kong
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. Announces Participation in Three September Investment Conferences
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorde...
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 25.81% and 51.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insuran...
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disord...
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.